Medicare THC Prescriptions Drop: State Disparities Revealed
A study examining tetrahydrocannabinol (THC) prescribing patterns among Medicare patients revealed a significant decline in dronabinol prescriptions from 2013 to 2019, alongside pronounced state-level disparities. Dronabinol, a synthetic form of THC, is a Schedule III controlled substance approved by the FDA primarily for managing chemotherapy-induced nausea and vomiting (CINV) and stimulating appetite in patients with AIDS-related anorexia and weight loss. While offering these therapeutic benefits, potential risks include psychiatric side effects like paranoia and hallucinations, dizziness, abdominal discomfort, and a risk of abuse or dependence.
The research indicated an overall 45% drop in prescribing rates, from 17.1 to 9.4 prescriptions per 1,000 Medicare beneficiaries, with associated costs decreasing by 64%. This decline is largely attributed to the increasing legalization and accessibility of medical cannabis across various states, suggesting that patients and physicians may be opting for whole-plant cannabis alternatives. However, the most striking finding was the vast difference in prescribing rates between states. For example, in 2019, states like Massachusetts and New York recorded significantly higher rates (35.1 and 30.1 prescriptions per 1,000 beneficiaries, respectively) compared to Hawaii and Alaska, which had rates as low as 0.8 per 1,000 beneficiaries.
These disparities underscore a complex interplay of factors, including varying state medical cannabis laws, evolving clinical guidelines for conditions like CINV, and differing physician comfort levels with prescribing controlled substances. The study highlights the dynamic landscape of cannabis-related medicine and its impact on traditional pharmaceutical prescribing, pointing to potential cost savings for Medicare and a shift in patient care preferences.
